Logo image of UNCY

UNICYCIVE THERAPEUTICS INC (UNCY) Stock Fundamental Analysis

NASDAQ:UNCY - Nasdaq - US90466Y1038 - Common Stock - Currency: USD

0.6169  +0.01 (+1.15%)

After market: 0.6199 +0 (+0.49%)

Fundamental Rating

3

UNCY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While UNCY seems to be doing ok healthwise, there are quite some concerns on its profitability. UNCY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year UNCY has reported negative net income.
In the past year UNCY has reported a negative cash flow from operations.
In the past 5 years UNCY always reported negative net income.
In the past 5 years UNCY always reported negative operating cash flow.
UNCY Yearly Net Income VS EBIT VS OCF VS FCFUNCY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

UNCY has a Return On Assets (-62.47%) which is comparable to the rest of the industry.
With a Return On Equity value of -86.52%, UNCY perfoms like the industry average, outperforming 49.91% of the companies in the same industry.
Industry RankSector Rank
ROA -62.47%
ROE -86.52%
ROIC N/A
ROA(3y)-305.08%
ROA(5y)-2579.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
UNCY Yearly ROA, ROE, ROICUNCY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -5K -10K

1.3 Margins

UNCY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UNCY Yearly Profit, Operating, Gross MarginsUNCY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -1K -2K -3K -4K

More info and screens

6

2. Health

2.1 Basic Checks

UNCY does not have a ROIC to compare to the WACC, probably because it is not profitable.
UNCY has more shares outstanding than it did 1 year ago.
The number of shares outstanding for UNCY has been increased compared to 5 years ago.
There is no outstanding debt for UNCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
UNCY Yearly Shares OutstandingUNCY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M
UNCY Yearly Total Debt VS Total AssetsUNCY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

UNCY has an Altman-Z score of -0.96. This is a bad value and indicates that UNCY is not financially healthy and even has some risk of bankruptcy.
UNCY has a Altman-Z score of -0.96. This is comparable to the rest of the industry: UNCY outperforms 58.97% of its industry peers.
There is no outstanding debt for UNCY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.96
ROIC/WACCN/A
WACC9.44%
UNCY Yearly LT Debt VS Equity VS FCFUNCY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

A Current Ratio of 3.61 indicates that UNCY has no problem at all paying its short term obligations.
UNCY's Current ratio of 3.61 is in line compared to the rest of the industry. UNCY outperforms 42.45% of its industry peers.
UNCY has a Quick Ratio of 3.61. This indicates that UNCY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.61, UNCY is in line with its industry, outperforming 44.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 3.61
UNCY Yearly Current Assets VS Current LiabilitesUNCY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.80% over the past year.
The Revenue for UNCY has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)40.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.54%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.34% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 277.28% on average over the next years. This is a very strong growth
EPS Next Y68.07%
EPS Next 2Y36.71%
EPS Next 3Y38.12%
EPS Next 5Y20.34%
Revenue Next Year-100%
Revenue Next 2Y696.29%
Revenue Next 3Y755.86%
Revenue Next 5Y277.28%

3.3 Evolution

UNCY Yearly Revenue VS EstimatesUNCY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
UNCY Yearly EPS VS EstimatesUNCY Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

UNCY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year UNCY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UNCY Price Earnings VS Forward Price EarningsUNCY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UNCY Per share dataUNCY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as UNCY's earnings are expected to grow with 38.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.71%
EPS Next 3Y38.12%

More info and screens

0

5. Dividend

5.1 Amount

UNCY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

UNICYCIVE THERAPEUTICS INC

NASDAQ:UNCY (2/21/2025, 8:00:01 PM)

After market: 0.6199 +0 (+0.49%)

0.6169

+0.01 (+1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)N/A N/A
Inst Owners60.39%
Inst Owner Change-76.7%
Ins Owners6.12%
Ins Owner Change0%
Market Cap64.03M
Analysts81.67
Price Target5.61 (809.39%)
Short Float %0.84%
Short Ratio0.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.48%
Min EPS beat(2)23.28%
Max EPS beat(2)67.68%
EPS beat(4)2
Avg EPS beat(4)-55.91%
Min EPS beat(4)-285.83%
Max EPS beat(4)67.68%
EPS beat(8)3
Avg EPS beat(8)-51.18%
EPS beat(12)3
Avg EPS beat(12)-46.64%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)37.5%
EPS NQ rev (3m)35.71%
EPS NY rev (1m)8.36%
EPS NY rev (3m)30.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.3
P/tB 2.3
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0
BVpS0.27
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.47%
ROE -86.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-305.08%
ROA(5y)-2579.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 371.43%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 3.61
Altman-Z -0.96
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.54%
EPS Next Y68.07%
EPS Next 2Y36.71%
EPS Next 3Y38.12%
EPS Next 5Y20.34%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y696.29%
Revenue Next 3Y755.86%
Revenue Next 5Y277.28%
EBIT growth 1Y-47.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-140.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-141.07%
OCF growth 3YN/A
OCF growth 5YN/A